Will morphing boron-based inhibitors beat the β-lactamases?

Current Opinion in Chemical Biology

Volumn 50, Issue , 2019, Pages 101-110

  Krajnc, Alen ^a   Lang, Pauline A ^a   Panduwawala, Tharindi D ^a   Brem, Jürgen ^a   Schofield, Christopher J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; VABORBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BORON;

CRYSTALLOGRAPHY; DRUG STRUCTURE; ENZYME INHIBITOR COMPLEX; HYBRIDIZATION; REVIEW; STRUCTURE ACTIVITY RELATION; CHEMISTRY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BORON; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85064319209     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2019.03.001     Document Type: Review

References (71)

1. Demain, A.L., Sanchez, S., Microbial drug discovery: 80 years of progress. J Antibiot 62 (2009), 5–16.
2. Konaklieva, M.I., Molecular targets of β-lactam-based antimicrobials: beyond the usual suspects. Antibiotics 3 (2014), 128–142.
3. Hughes, D., Karlen, A., Discovery and preclinical development of new antibiotics. Ups J Med Sci 119 (2014), 162–169.
4. Scheffers, D.J., Pinho, M.G., Bacterial cell wall synthesis: new insights from localization studies. Microbiol Mol Biol Rev 69 (2005), 585–607.
5. Tipper, D.J., Strominger, J.L., Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A 54 (1965), 1133–1141.
6. Wang, D.Y., Abboud, M.I., Markoulides, M.S., Brem, J., Schofield, C.J., The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam. Future Med Chem 8 (2016), 1063–1084.
7. Abraham, E.P., Chain, E., An enzyme from bacteria able to destroy penicillin. Nature, 146, 1940, 837.
8. Drawz, S.M., Bonomo, R.A., Three decades of β-lactamase inhibitors. Clin Microbiol Rev 23 (2010), 160–201.
9. Munita, J.M., Arias, C.A., Mechanisms of antibiotic resistance. Microbiol Spectr, 4, 2016, 10.1128/microbiolspec.VMBF-0016-2015.
10. Ambler, R.P., The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 289 (1980), 321–331.
11. Hall, B.G., Barlow, M., Revised Ambler classification of β-lactamases. J Antimicrob Chemother 55 (2005), 1050–1051.
12. Knox, J.R., Moews, P.C., Frere, J.-M., Molecular evolution of bacterial β-lactam resistance. Chem Biol 3 (1996), 937–947.
13. Majiduddin, F.K., Materon, I.C., Palzkill, T.G., Molecular analysis of β-lactamase structure and function. J Med Microbiol 292 (2002), 127–137.
14. Palzkill, T., Metallo-β-lactamase structure and function. Ann N Y Acad Sci 1277 (2013), 91–104.
15. Papp-Wallace, K.M., Bonomo, R.A., New β-lactamase inhibitors in the clinic. Infect Dis Clin North Am 30 (2016), 441–464.
16. Lohans, C.T., Brem, J., Schofield, C.J., New Delhi metallo-β-lactamase 1 catalyzes avibactam and aztreonam hydrolysis. Antimicrob Agents Chemother, 61, 2017 e01224-e01217.
17. Ehmann, D.E., Jahić, H., Ross, P.L., Gu, R.-F., Hu, J., Kern, G., Walkup, G.K., Fisher, S.L., Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109 (2012), 11663–11668 Demonstration that the diazabicyclooctane Avibactam reacts reversibly with serine-β lactamases to form a hydrolytically stable acyl–enzyme complex.
18. Zhanel, G.G., Lawson, C.D., Adam, H., Schweizer, F., Zelenitsky, S., Lagace-Wiens, P.R., Denisuik, A., Rubinstein, E., Gin, A.S., Hoban, D.J., et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73 (2013), 159–177.
19. Abboud, M.I., Damblon, C., Brem, J., Smargiasso, N., Mercuri, P., Gilbert, B., Rydzik, A.M., Claridge, T.D.W., Schofield, C.J., Frère, J.-M., Interaction of avibactam with class B metallo-β-Lactamases. Antimicrob Agents Chemother 60 (2016), 5655–5662.
20. Clayden, J., Greeves, N., Warren, S.G., Organic Chemistry. edn 1, 2001, Oxford University Press, Oxford.
21. Yang, K.W., Feng, L., Yang, S.K., Aitha, M., LaCuran, A.E., Oelschlaeger, P., Crowder, M.W., New β-phospholactam as a carbapenem transition state analog: synthesis of a broad-spectrum inhibitor of metallo-β-lactamases. Bioorg Med Chem Lett 23 (2013), 5855–5859.
22. Abboud, M.I., Kosmopoulou, M., Krismanich, A.P., Johnson, J.W., Hinchliffe, P., Brem, J., Claridge, T.D.W., Spencer, J., Schofield, C.J., Dmitrienko, G.I., Cyclobutanone mimics of intermediates in metallo-β-lactamase catalysis. Chemistry 24 (2018), 5734–5737.
23. Diaz, D.B., Yudin, A.K., The versatility of boron in biological target engagement. Nat Chem 9 (2017), 731–742 Analysis of the reactions of electrophiles with biological functional groups leading to the conclusion that boron has unique chameleon-like properties.
24. Demetriades, M., Leung, I.K.H., Chowdhury, R., Chan, M.C., McDonough, M.A., Yeoh, K.K., Tian, Y.-M., Claridge, T.D.W., Ratcliffe, P.J., Woon, E.C.Y., et al. Dynamic combinatorial chemistry employing boronic acids/boronate esters leads to potent oxygenase inhibitors. Angew Chem Int Ed 51 (2012), 6672–6675.
25. Wu, X., Li, Z., Chen, X.X., Fossey, J.S., James, T.D., Jiang, Y.B., Selective sensing of saccharides using simple boronic acids and their aggregates. Chem Soc Rev 42 (2013), 8032–8048.
26. Hall, D.G., Boronic acids: preparation and applications in organic synthesis, medicine and materials. Hall, D.G., (eds.) Structure, Properties, and Preparation of Boronic Acid Derivatives: Overview of their Reactions and Applications, 2011, WILEY-VCH Verlag GmbH & Co. KGaa, Weinheim, 1–133.
27. Ness, S., Martin, R., Kindler, A.M., Paetzel, M., Gold, M., Jensen, S.E., Jones, J.B., Strynadka, N.C., Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 β-lactamase. Biochemistry 39 (2000), 5312–5321.
28. Mettam, W.M., Adams, L.B., CRC Handbook of Chemistry and Physics: A Ready-Reference Book of Chemical and Physical Data. edn 97, 2016, CRC Press, Boca Raton (Florida).
29. Cahill, S.T., Tyrrell, J.M., Navratilova, I.H., Calvopiña, K., Robinson, S.W., Lohans, C.T., McDonough, M.A., Cain, R., Fishwick, C.W.G., Avison, M.B., et al. Studies on the inhibition of AmpC and other β-lactamases by cyclic boronates. Biochim Biophys Acta Gen Subj 1863 (2019), 742–748.
30. Cahill, S.T., Cain, R., Wang, D.Y., Lohans, C.T., Wareham, D.W., Oswin, H.P., Mohammed, J., Spencer, J., Fishwick, C.W.G., McDonough, M.A., et al. Cyclic boronates inhibit all classes of β-lactamases. Antimicrob Agents Chemother, 61, 2017 e02260-e02216.
31. Cama, E., Shin, H., Christianson, D.W., Design of amino acid sulfonamides as transition-state analogue inhibitors of arginase. J Am Chem Soc 125 (2003), 13052–13057.
32. Field-Smith, A., Morgan, G.J., Davies, F.E., Bortezomib (Velcade trade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag 2 (2006), 271–279.
33. Huber, E.M., Heinemeyer, W., Groll, M., Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. Structure 23 (2015), 407–417.
34. Chauhan, D., Tian, Z., Zhou, B., Kuhn, D., Orlowski, R., Raje, N., Richardson, P., Anderson, K.C., In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 17 (2011), 5311–5321.
35. Zhao, H., Palencia, A., Seiradake, E., Ghaemi, Z., Cusack, S., Luthey-Schulten, Z., Martinis, S., Analysis of the resistance mechanism of a benzoxaborole inhibitor reveals insight into the leucyl-tRNA synthetase editing mechanism. ACS Chem Biol 10 (2015), 2277–2285.
36. Hecker, S.J., Reddy, K.R., Totrov, M., Hirst, G.C., Lomovskaya, O., Griffith, D.C., King, P., Tsivkovski, R., Sun, D., Sabet, M., et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58 (2015), 3682–3692.
37. Dhillon, S., Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs 78 (2018), 1259–1270.
38. Brem, J., Cain, R., Cahill, S., McDonough, M.A., Clifton, I.J., Jiménez-Castellanos, J.-C., Avison, M.B., Spencer, J., Fishwick, C.W.G., Schofield, C.J., Structural basis of metallo-β-lactamase, serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat Commun, 7, 2016, 12406 Demonstration by biochemical, crystallographic and microbiological analyses that bicyclic boronates have potential as broad spectrum inhibitors of serine-β-lactamases and metalo-β-lactamases.
39. Calvopina, K., Hinchliffe, P., Brem, J., Heesom, K.J., Johnson, S., Cain, R., Lohans, C.T., Fishwick, C.W.G., Schofield, C.J., Spencer, J., et al. Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates. Mol Microbiol 106 (2017), 492–504.
40. Michaelis, A., Becker, P., Ueber Monophenylborchlorid und einige Derivate desselben. Ber Dtsch Chem Ges 15 (1882), 180–185.
41. Dembitsky, V.M., Al Quntar, A.A., Srebnik, M., Natural and synthetic small boron-containing molecules as potential inhibitors of bacterial and fungal quorum sensing. Chem Rev 111 (2011), 209–237.
42. Dobozy, O., Mile, I., Ferencz, I., Csanyi, V., Effect of electrolytes on the activity and iodine sensitivity of penicillinase from B. cereus. Acta Biochim Biophys Acad Sci Hung 6 (1971), 97–105.
43. Beesley, T., Gascoyne, N., Knott-Hunziker, V., Petursson, S., Waley, S.G., Jaurin, B., Grundstrom, T., The inhibition of class C β-lactamases by boronic acids. Biochem J 209 (1983), 229–233.
44. Werner, J.P., Mitchell, J.M., Taracila, M.A., Bonomo, R.A., Powers, R.A., Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase. Protein Sci 26 (2017), 515–526.
45. Rojas, L.J., Taracila, M.A., Papp-Wallace, K.M., Bethel, C.R., Caselli, E., Romagnoli, C., Winkler, M.L., Spellberg, B., Prati, F., Bonomo, R.A., Boronic acid transition state inhibitors active against KPC and other class A β-lactamases: structure–activity relationships as a guide to inhibitor design. Antimicrob Agents Chemother 60 (2016), 1751–1759.
46. Chen, Y., Shoichet, B., Bonnet, R., Structure, function, and inhibition along the reaction coordinate of CTX-M β-lactamases. J Am Chem Soc 127 (2005), 5423–5434.
47. Drawz, S.M., Babic, M., Bethel, C.R., Taracila, M., Distler, A.M., Ori, C., Caselli, E., Prati, F., Bonomo, R.A., Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 49 (2010), 329–340.
48. Contreras-Martel, C., Amoroso, A., Woon, E.C., Zervosen, A., Inglis, S., Martins, A., Verlaine, O., Rydzik, A.M., Job, V., Luxen, A., et al. Structure-guided design of cell wall biosynthesis inhibitors that overcome β-lactam resistance in Staphylococcus aureus (MRSA). ACS Chem Biol 6 (2011), 943–951.
49. Dzhekieva, L., Adediran, S.A., Pratt, R.F., Interactions of “bora-penicilloates” with serine β-lactamases and DD-peptidases. Biochemistry 53 (2014), 6530–6538 Studies on the interaction of penicilloanate analogues in which the β-lactam derived carboxylate is replaced with a boronic acid.
50. Cox, J.D., Kim, N.N., Traish, A.M., Christianson, D.W., Arginase-boronic acid complex highlights a physiological role in erectile function. Nat Struct Biol 6 (1999), 1043–1047.
51. Di Costanzo, L., Sabio, G., Mora, A., Rodriguez, P.C., Ochoa, A.C., Centeno, F., Christianson, D.W., Crystal structure of human arginase I at 1.29-Å resolution and exploration of inhibition in the immune response. Proc Natl Acad Sci U S A 102 (2005), 13058–13063.
52. Burns CJ, Goswami R, Chu G-H, Jackson RW, Hamrick J, Lucas M, Boyd SA, Yao J, Mesaros EF: Penicillin-binding protein inhibitors. WO2018218190, November 29 2018.
53. VenatoRx, VenatoRx Pharmaceuticals to present its lead clinical antibacterial candidate, VNRX-5133. American Chemical Society National Meeting, 2018 Reveals the bicyclic boronate VNRX-5133 as a broad-spectrum β-lactamase inhibitor.
54. Macheboeuf, P., Fischer, D.S., Brown, T. Jr, Zervosen, A., Luxen, A., Joris, B., Dessen, A., Schofield, C.J., Structural and mechanistic basis of penicillin-binding protein inhibition by lactivicins. Nat Chem Biol 3 (2007), 565–569.
55. Burns CJ, Goswami R, Jackson RW, Lessen T, Li W, Pevear D, Tirunahari PK, Xu H: Beta-lactamase inhibitors. US20160264598, September 15 2016.
56. Pogue, J.M., Bonomo, R.A., Kaye, K.S., Ceftazidime/Avibactam, Meropenem/Vaborbactam, or both? Clinical and formulary considerations. Clin Infect Dis 68 (2018), 519–524.
57. Jia, L., Liu, F.T., Why bortezomib cannot go with ‘green’?. Cancer Biol Med 10 (2013), 206–213.
58. Miller, S.T., Xavier, K.B., Campagna, S.R., Taga, M.E., Semmelhack, M.F., Bassler, B.L., Hughson, F.M., Salmonella typhimurium recognizes a chemically distinct form of the bacterial quorum-sensing signal AI-2. Mol Cell 15 (2004), 677–687.
59. Hutter, R., Keller-Schierlein, W., Knusel, F., Prelog, V., Rodgers, G.C. Jr., Suter, P., Vogel, G., Voser, W., Zahner, H., The metabolic products of microorganisms. Boromycin. Helv Chim Acta 50 (1967), 1533–1539.
60. Moore, B.S., Hertweck, C., Biosynthesis and attachment of novel bacterial polyketide synthase starter units. Nat Prod Rep 19 (2002), 70–99.
61. Uluisik, I., Karakaya, H.C., Koc, A., The importance of boron in biological systems. J Trace Elem Med Biol 45 (2018), 156–162.
62. Guo, M., Gamby, S., Zheng, Y., Sintim, H.O., Small molecule inhibitors of AI-2 signalling in bacteria: state-of-the-art and future perspectives for anti-quorum sensing agents. Int J Mol Sci 14 (2013), 17694–17728.
63. Dunitz, J.D., Hawley, D.M., Miklos, D., White, D.N., Berlin, Y., Marusic, R., Prelog, V., Structure of boromycin. Helv Chim Acta 54 (1971), 1709–1713.
64. Han, S., Zaniewski, R.P., Marr, E.S., Lacey, B.M., Tomaras, A.P., Evdokimov, A., Miller, J.R., Shanmugasundaram, V., Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 107 (2010), 22002–22007.
65. Smith, C.A., Antunes, N.T., Stewart, N.K., Toth, M., Kumarasiri, M., Chang, M., Mobashery, S., Vakulenko, S.B., Structural basis for carbapenemase activity of the OXA-23 β-lactamase from Acinetobacter baumannii. Chem Biol 20 (2013), 1107–1115.
66. Feng, H., Liu, X., Wang, S., Fleming, J., Wang, D.C., Liu, W., The mechanism of NDM-1-catalyzed carbapenem hydrolysis is distinct from that of penicillin or cephalosporin hydrolysis. Nat Commun, 8, 2017, 2242.
67. Cama, E., Pethe, S., Boucher, J.L., Han, S., Emig, F.A., Ash, D.E., Viola, R.E., Mansuy, D., Christianson, D.W., Inhibitor coordination interactions in the binuclear manganese cluster of arginase. Biochemistry 43 (2004), 8987–8999.
68. Alterio, V., Cadoni, R., Esposito, D., Vullo, D., Fiore, A.D., Monti, S.M., Caporale, A., Ruvo, M., Sechi, M., Dumy, P., et al. Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. Chem Commun 52 (2016), 11983–11986.
69. Morandi, F., Caselli, E., Morandi, S., Focia, P.J., Blazquez, J., Shoichet, B.K., Prati, F., Nanomolar inhibitors of AmpC β-lactamase. J Am Chem Soc 125 (2003), 685–695.
70. Zervosen, A., Herman, R., Kerff, F., Herman, A., Bouillez, A., Prati, F., Pratt, R.F., Frere, J.M., Joris, B., Luxen, A., et al. Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J Am Chem Soc 133 (2011), 10839–10848.
71. McKinney, D.C., Zhou, F., Eyermann, C.J., Ferguson, A.D., Prince, D.B., Breen, J., Giacobbe, R.A., Lahiri, S., Verheijen, J.C., 4,5-Disubstituted 6-aryloxy-1,3-dihydrobenzo[c][1,2]oxaboroles are broad-spectrum serine beta-lactamase inhibitors. ACS Infect Dis 1 (2015), 310–316.